{"title":"上尿路尿路上皮肿瘤根治性肾切除术后膀胱内复发的危险因素:回顾性单中心研究","authors":"T. Kargı, M. Ekşi","doi":"10.33719/yud.2022;17-3-1115325","DOIUrl":null,"url":null,"abstract":"Objective: We examined factors predicting metachronous recurrence of bladder cancer in our series of patients who underwent radical nephroureterectomy (RNU) for upper system urothelial carcinoma (UTUC). Material and Methods: Patients with UTUC-induced RNU in our center from September 2009 to March 2020 were included in the study. Patients were classified as having and not having an intravesical recurrence (IVR), and the factors predicting recurrence were evaluated. Results: A total of 50 patients were included in the study. IVR was developed in 19 (38%) of 50 patients, with a mean follow-up of 39.5 ± 25.3 months. There was no significant difference between the two groups in demographic characteristics, admission hemoglobin, glomerular filtration rate, and degree of hydronephrosis in preoperative ureterorenoscopy and cytology positivity history (p>0.05). The IVR (+) group had significantly more previous history of bladder cancer (35.5% vs. 52.6%, p=0.019, respectively). While the number of patients with ureteral tumors was 10 (32.3%) in the IVR (-) group, it was 9 (47.4%) in the IVR (+) group, and it was significantly higher. There are 28 (56%) patients with T2-T4 pathology in the entire patient group, and the rate is significantly greater in the IVR (+) group (63.2% vs. 51.6%, p=0.038, respectively). Conclusion: Caution should be exercised for metachronous bladder cancer recurrence in patients with a previous history of bladder cancer, especially in ureteral and high pathological T-stage UTUCs. Keywords: upper urinary tract urothelial carcinoma, intravesical recurrence, risk factor, nephroureterectomy","PeriodicalId":33828,"journal":{"name":"Yeni Uroloji Dergisi","volume":"44 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk factors for intravesical recurrence after radical nephrourethrectomy in upper urinary tract urothelial tumors: retrospective single-center study\",\"authors\":\"T. Kargı, M. Ekşi\",\"doi\":\"10.33719/yud.2022;17-3-1115325\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: We examined factors predicting metachronous recurrence of bladder cancer in our series of patients who underwent radical nephroureterectomy (RNU) for upper system urothelial carcinoma (UTUC). Material and Methods: Patients with UTUC-induced RNU in our center from September 2009 to March 2020 were included in the study. Patients were classified as having and not having an intravesical recurrence (IVR), and the factors predicting recurrence were evaluated. Results: A total of 50 patients were included in the study. IVR was developed in 19 (38%) of 50 patients, with a mean follow-up of 39.5 ± 25.3 months. There was no significant difference between the two groups in demographic characteristics, admission hemoglobin, glomerular filtration rate, and degree of hydronephrosis in preoperative ureterorenoscopy and cytology positivity history (p>0.05). The IVR (+) group had significantly more previous history of bladder cancer (35.5% vs. 52.6%, p=0.019, respectively). While the number of patients with ureteral tumors was 10 (32.3%) in the IVR (-) group, it was 9 (47.4%) in the IVR (+) group, and it was significantly higher. There are 28 (56%) patients with T2-T4 pathology in the entire patient group, and the rate is significantly greater in the IVR (+) group (63.2% vs. 51.6%, p=0.038, respectively). Conclusion: Caution should be exercised for metachronous bladder cancer recurrence in patients with a previous history of bladder cancer, especially in ureteral and high pathological T-stage UTUCs. Keywords: upper urinary tract urothelial carcinoma, intravesical recurrence, risk factor, nephroureterectomy\",\"PeriodicalId\":33828,\"journal\":{\"name\":\"Yeni Uroloji Dergisi\",\"volume\":\"44 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Yeni Uroloji Dergisi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33719/yud.2022;17-3-1115325\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Yeni Uroloji Dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33719/yud.2022;17-3-1115325","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:研究在接受根治性肾输尿管切除术(RNU)治疗上系统尿路上皮癌(UTUC)的患者中膀胱癌异时性复发的预测因素。材料与方法:本研究纳入2009年9月至2020年3月在我中心收治的utuc致RNU患者。将患者分为有无膀胱内复发(IVR),并对预测复发的因素进行评估。结果:共纳入50例患者。50例患者中有19例(38%)出现IVR,平均随访39.5±25.3个月。两组患者人口学特征、入院血红蛋白、肾小球滤过率、术前输尿管镜及细胞学阳性史肾积水程度差异无统计学意义(p < 0.05)。IVR(+)组膀胱癌既往病史明显增加(35.5% vs. 52.6%, p=0.019)。输尿管肿瘤患者中,IVR(-)组为10例(32.3%),IVR(+)组为9例(47.4%),两者差异有统计学意义。整个患者组中出现T2-T4病理的患者有28例(56%),其中IVR(+)组出现T2-T4病理的患者比例明显高于IVR(+)组(63.2%比51.6%,p=0.038)。结论:对于既往有膀胱癌病史的患者,尤其是输尿管和高病理t期UTUCs患者,应谨慎对待异时性膀胱癌复发。关键词:上尿路尿路上皮癌,膀胱内复发,危险因素,肾输尿管切除术
Risk factors for intravesical recurrence after radical nephrourethrectomy in upper urinary tract urothelial tumors: retrospective single-center study
Objective: We examined factors predicting metachronous recurrence of bladder cancer in our series of patients who underwent radical nephroureterectomy (RNU) for upper system urothelial carcinoma (UTUC). Material and Methods: Patients with UTUC-induced RNU in our center from September 2009 to March 2020 were included in the study. Patients were classified as having and not having an intravesical recurrence (IVR), and the factors predicting recurrence were evaluated. Results: A total of 50 patients were included in the study. IVR was developed in 19 (38%) of 50 patients, with a mean follow-up of 39.5 ± 25.3 months. There was no significant difference between the two groups in demographic characteristics, admission hemoglobin, glomerular filtration rate, and degree of hydronephrosis in preoperative ureterorenoscopy and cytology positivity history (p>0.05). The IVR (+) group had significantly more previous history of bladder cancer (35.5% vs. 52.6%, p=0.019, respectively). While the number of patients with ureteral tumors was 10 (32.3%) in the IVR (-) group, it was 9 (47.4%) in the IVR (+) group, and it was significantly higher. There are 28 (56%) patients with T2-T4 pathology in the entire patient group, and the rate is significantly greater in the IVR (+) group (63.2% vs. 51.6%, p=0.038, respectively). Conclusion: Caution should be exercised for metachronous bladder cancer recurrence in patients with a previous history of bladder cancer, especially in ureteral and high pathological T-stage UTUCs. Keywords: upper urinary tract urothelial carcinoma, intravesical recurrence, risk factor, nephroureterectomy